World wide experience with inactivated poliovirus vaccine

Vaccine

Volumn 26, Issue 39, 2008, Pages 4978-4983

  Bonnet, Marie Claude ^a   Dutta, Anil ^a  

^a SANOFI PASTEUR   (France)

Author keywords

Immunization programs; Inactivated poliovirus vaccine; Polio eradication; Vaccine associated paralytic poliomyelitis; Vaccine derived poliovirus

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; INACTIVATED VACCINE; NEUTRALIZING ANTIBODY; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

ANTIBODY RESPONSE; DRUG SAFETY; HEALTH PROGRAM; HUMAN; IMMUNOGENICITY; OUTCOME ASSESSMENT; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; VACCINATION;

HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; RISK ASSESSMENT; WORLD HEALTH;

EID: 50849144023     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.026     Document Type: Review

References (44)

1. Chan M. The World Health Organization, The case for completing polio eradication, Accessed June 26, 2008. http://www.polioeradication.org/caseforpolioeradication.asp.
2. Arita I. Is polio eradication realistic?. Science 312 (2006) 852-854
3. Thompson K.M., and Tebbens R.J. Eradication versus control for poliomyelitis: an economic analysis. Lancet 369 (2007) 1363-1371
4. Aylward R.B., Hull H.F., Cochi S.L., Sutter R.W., Olive J.-M., and Melgaard B. Disease eradication as a public health strategy: a case study of poliomyelitis eradication. Bull World Health Organ 78 (2000) 285-297
5. Hull H.F. Progress towards polio eradication. Dev Biol 105 (2001) 3-7
6. Grassly N.C., Wenger J., Durrani S., Bahl S., Deshpande J.M., Sutter R.W., et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet 369 (2007) 1356-1362
7. Update on vaccine-derived polioviruses-worldwide, January 2006-August 2007, MMWR 2007;56:996-1001.
8. Paul Y. Herd immunity and herd protection. Vaccine 22 (2004) 301-302
9. John T.J., and Samuel R. Herd immunity and herd effect: new insights and definitions. Eur J Epidemiol 16 (2000) 601-606
10. Vidor E., Meschievitz C., and Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr Infect Dis J 16 (1997) 312-322
11. Plotkin S.A., and Vidor E. Poliovirus vaccine-inactivated. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 4th ed. (2004), Saunders Company 625-649
12. Cuba IPV Study Collaborative Group. Randomized, Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba. N Engl J Med 356 (2007) 1536-1544
13. Rumke H.C., Oostvogel P.M., Van Steenis G., and Van Loon A.M. Poliomyelitis in the Netherlands: a review of population immunity and exposure between the epidemics in 1978 and 1992. Epidemiol Infect 115 (1995) 289-295
14. Oostvogel P.M., van Wijngaarden J.K., van der Avoort H.G., Mulders M.N., Conyn-van Spaendonck M.A., Rumke H.C., et al. Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-1993. Lancet 344 8923 (1994) 665-670
15. Conyn-van Spaendonck M.A., Oostvogel P.M., van Loon A.M., van Wijngaarden J.K., and Kromhout D. Circulation of poliovirus during the poliomyelitis outbreak in the Netherlands in 1992-1993. Am J Epidemiol 143 (1996) 929-935
16. Varughese P., Carter A.O., Acres S.E., and Furesz J. Eradication of indigenous poliomyelitis in Canada: impact of immunization strategies. Can J Public Health 80 (1989) 363-368
17. Murdin A.D., Barreto L., and Plotkin S. Inactivated poliovirus vaccine:past and present experience. Vaccine 14 (1996) 735-746
18. Böttiger M., and Fagraeus A. Polio vaccination in Sweden. Rev Infect Dis 2 (1980) 274-276
19. Böttiger M., Mellin P., Romanus V., Söderstrom H., Wesslen T., and von Zeipel G. Epidemiological events surrounding a paralytic case of poliomyelitis in Sweden. Bull WHO 57 (1979) 99-103
20. Lapinleimu K. Elimination of poliomyelitis in Finland. Rev Infect Dis 6 Suppl. 2 (1984) S457-S460
21. Böttiger M., and Herrstrom E. Isolation of polioviruses from sewage and their characteristics: experience over two decades in Sweden. Scand J Infect Dis 24 (1992) 151-155
22. Stickle G. Observed and expected cases of poliomyelitis in the United States, 1958-1964. Am J Public Health 54 (1961) 1222-1229
23. Schonberger L.B., Kaplan J., Kim-Farley R., Moore M., Eddins D.L., and Hatch M. Control of paralytic poliomyelitis in the United States. Rev Infect Dis 6 Suppl. 2 (1984) S424-S426
24. Robertson S.E., Traverso H.P., Drucker J.A., Rovira E.Z., Fabre-Teste B., Sow A., et al. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. Lancet (1988) 897-899
25. Rümke H.C., Schlumberger M., Floury B., Nagel J., and van Steenis B. Serological evaluation of a simplified immunization schedule using quadruple DPT-polio vaccine in Burkina Faso. Vaccine 11 (1993) 1113-1118
26. Moriniere B.J., van Loon F.P., Rhodes P.H., Klein-Zabban M.L., Frank-Senat B., Herrington J.E., et al. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet 341 (1993) 1545-1550
27. Huang Q.S., Greening G., Baker M.G., Grimwood K., Hewitt J., and Hulston D. Persistance of oral polio vaccine after its removal from the immunisation schedule in New Zealand. Lancet 366 9483 (2005) 394-396
28. Australian Government Department of Health and Ageing, Immunisation programs and initiatives, Accessed June 26, 2008. http://immunise.health.gov.au/internet/immunise/publishing.nsf/Content/p rograms.
29. Gidding H.F., Backhouse J.L., Gilbert G.L., and Burgess M.A. National serosurvey of poliovirus immunity in Australia, 1996-99. Aust N Z J Public Health 29 (2005) 48-52
30. Lim F.S., Han H.H., Jacquet J.M., and Bock H.L. Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine. Ann Acad Med Singapore 36 (2007) 801-806
31. Simasathien S., Migasena S., Beuvery C., van Steenis G., Samakoses R., Pitisuttitham P., et al. Comparison of enhanced potency inactivated poliovirus vaccine (EIPV) versus standard oral poliovirus (OPV) in Thai infants. Scand J Infect Dis 26 (1994) 731-738
32. Lin T.Y., Wang Y.H., Chang L.Y., Chiu C.H., Huang Y.C., Tang H., et al. Safety and immunogenicity of a diphtheria, tetanus and acellular pertussis-inactivated poliovirus vaccine/Haemophilus influenzae type B combination vaccine administered to Taiwanese infants at 2, 4, and 6 months of age. Chang Gung Med J 26 (2003) 315-322
33. John T.J. Will India need inactivated poliovirus vaccine (IPV) to complete polio eradication?. Indian J Med Res 122 (2005) 365-367
34. Mittal S.K., and Mathew J.L. Polio eradication in India: the way forward. Indian J Pediatr 74 (2007) 153-160
35. Krishnan R., Jadhav M., Selvakumar R., and John T.J. Immune response of infants in the tropics to injectable polio vaccine. BMJ 284 (1982) 164
36. Krishnan R., Jadhay M., and John T.J. Efficacy of inactivated poliovirus vaccine in India. Bull World Health Organ 61 (1983) 689-692
37. John T.J., Selvakumar R., Balraj V., and Rajarathinam A. Field studies using killed poliovirus vaccine. Proceedings of the Third International Seminar on Vaccination in Africa. Niger. Paris: Association for the Promotion of Preventive Medicine (1987) 173-181
38. John T.J. Immunization against polioviruses in developing countries. Rev Med Virol 3 (1993) 149-160
39. John T.J. The golden jubilee of vaccination against poliomyelitis. Indian J Med Res 119 (2004) 1-17
40. Asturias E.J., Dueger E.L., Omer S.B., Melville A., Nates S.V., Laassri M., et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. J Infect Dis 196 (2007) 692-698
41. Dayan G.H., Thorley M., Yamamura Y., Rodriguez M., McLaughlin S., Torres L.M., et al. Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J Infect Dis 195 (2007) 12-20
42. Lagos R., Kotloff K., Hoffenbach A., San Martin O., Abrego P., Ureta A.M., et al. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants. Pediatr Infect Dis J 17 (1998) 294-304
43. Araújo O.O., Forleo-Neto E., Vespa G.N., Puccini R.F., Weckx L.W., Carvalho E.S., et al. Associated or combined vaccination of Brazilian infants with a conjugate Haemophilus infuenzae type b (Hib) vaccine, a diphtheria, tetanus, whole-cell pertussis vaccine and IPV or OPV elicits protective levels of antibodies against Hib. Vaccine 19 (2001) 367-375
44. Renteria y Cárdenas Armando. La cartilla nacional de vacunación de México para 2007. Arch Invest Pediátr Méx 2007;10(1):3-4.